1-[4-[2-(1-Piperidinyl)ethoxy]-phenoxy]-2-(3-hydroxyphenyl)-6-methoxynaphthalene | 203872-36-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-[4-[2-(1-Piperidinyl)ethoxy]-phenoxy]-2-(3-hydroxyphenyl)-6-methoxynaphthalene
• 英文别名: 3-[6-methoxy-1-[4-(2-piperidin-1-ylethoxy)phenoxy]naphthalen-2-yl]phenol
• CAS: 203872-36-0
• 化学式: C₃₀H₃₁NO₄
• 分子量: 469.58
• InChiKey: GBVWAOUOQFCTAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[4-[2-(1-Piperidinyl)ethoxy]-phenoxy]-2-(3-hydroxyphenyl)-6-methoxynaphthalene 在 三溴化硼 作用下， 生成 6-(3-Hydroxyphenyl)-5-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)naphthalen-2-ol
  参考文献：
  名称：

  Structure–activity relationships of SERMs optimized for uterine antagonism and ovarian safety

  摘要：

  Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.044
• 作为产物：
  描述：

  1-溴-6-甲氧基-2-萘酚 在 palladium diacetate 、 palladium dihydroxide 甲酸铵 、 三氟甲烷磺酸亚铜(I)苯联合体 (2:1) 、 cesium fluoride 、 三环己基膦 作用下， 反应 4.0h， 生成 1-[4-[2-(1-Piperidinyl)ethoxy]-phenoxy]-2-(3-hydroxyphenyl)-6-methoxynaphthalene
  参考文献：
  名称：

  Structure–activity relationships of SERMs optimized for uterine antagonism and ovarian safety

  摘要：

  Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.044

文献信息

• Naphthyl compounds, intermediates, compositions, and methods of use
  申请人：——

  公开号：US20040072820A1

  公开（公告）日：2004-04-15

  The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use.

  本发明提供了新型的取代萘基化合物、中间体、组合物、药物配方和使用方法。
• Naphthyl compounds, intermediates, compositions, and method of use
  申请人：ELI LILLY AND COMPANY

  公开号：EP0826679A2

  公开（公告）日：1998-03-04

  The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use. The novel naphthyl compounds have the formula wherein R1 is -H, -OH, -O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -O(CO)OAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R2 is -H, -F, -Cl, -OH, -O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -O(CO)OAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R3 and R4 are, independently, -H, -F, -Cl, -CH3, -OH,-O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or-OSO2(C4-C6 alkyl), with the proviso that both R3 and R4 cannot be hydrogen; n is 2 or 3; and R5 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt or solvate thereof.

  本发明提供了新型取代萘化合物、中间体、组合物、药物制剂和使用方法。这些新型萘化合物具有如下式子 式中 R1 是-H、-OH、-O(C1-C4 烷基)、-OCOAr（其中 Ar 是苯基或取代苯基）、-O(CO)OAr（其中 Ar 是苯基或取代苯基）、-OCO(C1-C6 烷基)、-O(CO)O(C1-C6 烷基)或-OSO2(C4-C6 烷基)； R2 是-H、-F、-Cl、-OH、-O(C1-C4 烷基)、-OCOAr（其中 Ar 是苯基或取代苯基）、-O(CO)OAr（其中 Ar 是苯基或取代苯基）、-OCO(C1-C6 烷基)、-O(CO)O(C1-C6 烷基)或-OSO2(C4-C6 烷基)； R3 和 R4 独立地是-H、-F、-Cl、-CH3、-OH、-O(C1-C4 烷基)、-OCOAr（其中 Ar 是苯基或取代苯基）、-OCO(C1-C6 烷基)、-O(CO)O(C1-C6 烷基)或-OSO2(C4-C6 烷基)，但 R3 和 R4 不能都是氢； n 是 2 或 3；以及 R5 是 1-哌啶基、1-吡咯烷基、甲基-1-吡咯烷基、二甲基-1-吡咯烷基、4-吗啉基、二甲基氨基、二乙基氨基或 1-六亚甲基亚氨基；或其药学上可接受的盐或溶液。
• Naphthyl and tetralone derivatives as intermediates
  申请人：ELI LILLY AND COMPANY

  公开号：EP1142862A2

  公开（公告）日：2001-10-10

  The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use. The novel naphthyl compounds have the formula wherein R1 is -H, -OH, -O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -O(CO)OAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R2 is -H, -F, -Cl, -OR, -O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -O(CO)OAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R3 and R4 are, independently, -H, -F, -Cl, -CH3, -OH, -O(C1-C4 alkyl), -OCOAr where Ar is phenyl or substituted phenyl, -OCO(C1-C6 alkyl), -O(CO)O(C1-C6 alkyl), or -OSO2(C4-C6 alkyl), with the proviso that both R3 and R4 cannot be hydrogen; n is 2 or 3; and R5 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt or solvate thereof.

  本发明提供了新型取代萘化合物、中间体、组合物、药物制剂和使用方法。这些新型萘化合物具有如下式子 式中 R1 是-H、-OH、-O(C1-C4 烷基)、-OCOAr（其中 Ar 是苯基或取代苯基）、-O(CO)OAr（其中 Ar 是苯基或取代苯基）、-OCO(C1-C6 烷基)、-O(CO)O(C1-C6 烷基)或-OSO2(C4-C6 烷基)； R2 是-H、-F、-Cl、-OR、-O(C1-C4 烷基)、-OCOAr（其中 Ar 是苯基或取代苯基）、-O(CO)OAr（其中 Ar 是苯基或取代苯基）、-OCO(C1-C6 烷基)、-O(CO)O(C1-C6 烷基)或-OSO2(C4-C6 烷基)； R3 和 R4 独立地是-H、-F、-Cl、-CH3、-OH、-O(C1-C4 烷基)、-OCOAr（其中 Ar 是苯基或取代苯基）、-OCO(C1-C6 烷基)、-O(CO)O(C1-C6 烷基)或-OSO2(C4-C6 烷基)，但 R3 和 R4 不能都是氢； n 是 2 或 3；以及 R5 是 1-哌啶基、1-吡咯烷基、甲基-1-吡咯烷基、二甲基-1-吡咯烷基、4-吗啉基、二甲基氨基、二乙基氨基或 1-六亚甲基亚氨基；或其药学上可接受的盐或溶液。
• Naphthyl compounds and compositions
  申请人：ELI LILLY AND COMPANY

  公开号：EP0826679B1

  公开（公告）日：2001-11-21
• US6593345B1
  申请人：——

  公开号：US6593345B1

  公开（公告）日：2003-07-15